The FDA has launched the Commissioner’s National Priority Voucher (CNPV) program, offering 1-2 month reviews, so drug developers can get faster market access for products that align with national priorities. Some examples could be:
1. Strengthening US employment in development & manufacturing
2. Ensuring that clinical trials have robust US patient population
3. Affordability of drug products by lowering drug prices or reducing downstream healthcare costs
4. Delivering innovative, truly transformative therapies

This could boost US employment in early research, development, and GMP manufacturing. It could accelerate patient access to important medications.

However, it raises some concerns:
1. Is a 60-day review sufficient to make safety & efficacy decisions?
2. Will the expedited review further strain the FDA’s resources and delay other approvals?
3. Will rare disease clinical trials be delayed if we don’t have enough US cases to ensure robust representation?
4. Is it possible to ensure affordable pricing for a sustained period after approval?
5. With the affordability requirement, will companies still invest in high-risk, innovative research if it will take long to recover R&D costs?

Note: A version of this was shared by me in a LinkedIn post.